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Sciences, Tehran, Iran
There is growing evidence that neurotrophins besides their well-established actions in regulating the survival, differentiation, 
and maintenance of the functions of specific populations of neurons, act as the potential mediators of antidepressant responses. 
Previous studies on the regulation of nerve growth factor (NGF) levels by psychotropic medications are limited in scope and the 
underlying mechanism(s) remain elusive. In this review, the latest findings on the effects of pharmacologically heterogeneous 
groups of psychotropic drugs on NGF contents in the brain regions involved in the modulation of emotions are summarized. 
Moreover, the therapeutic potentials of the endocannabinoid system which is linked to depression and/or antidepressant effects 
and appears to interact with neurotrophin signalling, are reviewed. New findings demonstrate that endocannabinoid system is 
involved in the mechanisms of action of certain psychotropic medications including neurokinin receptor antagonists and that 
these are mediated via the upregulation of brain regional levels of NGF. This provides a better understanding of the pathophysi-
ological mechanisms underlying neuropsychiatric disorders, leading to novel drug designs. Biomed Rev 2010; 21: 31-46.
Key words: endocannabinoids, NGF, psychotropics, brain
INTRODUCTION 
Depression is a serious and widespread mental disorder with 
high relapse rate which is characterized by an array of dis-
turbances in emotional behavior, memory, neurovegetative 
functions and hedonic processing (1). The neurobiological 
mechanisms subserving the development, manifestation, 
and treatment of depression are complex. There is ample 
evidence that disturbances in monoaminergic signalling and 
glucocorticoid activity are involved in the pathophysiology 
of depression (2-4). However, the monoamine-based anti-
depressants do not fulfil the expectations in terms of onset 
of action, efficacy, and tolerability. This urges the need for 
the development of new antidepressants with novel mecha-
nisms of action. Recent studies suggest a novel - neuropro-
tective - role for the adipose-derived hormone (adipokine) 
leptin, which was originally discovered to control energy 
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homeostasis and body weight. Indeed, the localization of 
leptin receptor in limbic structures prompted the research-
ers to investigate the therapeutic potential of leptin in animal 
models of depression (5,6). In parallel, there has been grow-
ing interest in the assessment of the effects of psychotropic 
drugs on intraneuronal signal transduction and neurotrophins 
(7,8). Neurotrophins are family of proteins consisting of 
nerve growth factor (NGF), brain-derived neurotrophic fac-
tor (BDNF), neurotrophin 3 (NT-3), NT-4/5, and NT-6 which 
regulate the survival, development, and function of neurons 
(9,10); both pro-NGF and pro-BDNF should also be appreci-
ated. The cellular actions of neurotrophins are mediated by 
two types of receptors; a high affinity tyrosine kinase (Trk) 
receptor, and a low affinity pan-neurotrophin receptor (p75N-
TR). Each Trk receptor is preferentially activated by one or 
more neurotrophin; TrkA by NGF, TrkB by BDNF and NT-
4/5, and TrkC by NT-3 (Fig. 1), leading to a number of cel-
lular responses (11). Although the long-term trophic effects 
of neurotrophins depend on gene regulation, the cytoplasmic 
effectors activated by neurotrophins exert a wide range of 
more rapid actions including morphogenetic and chemo-
tropic effects on developing neurons (12-14), modulation of 
neuronal excitability (15), and synaptic transmission (16,17). 
Neurotrophins are also involved in the specific aspects of 
neuronal plasticity (18,19), a term used to describe a great 
variety of changes in neuronal structure and function. Neu-
rotrophins exert neuroprotective effects under pathological 
conditions which might be important for neurodegenerative 
and psychiatric diseases (20). Dysfunction in neurotrophin-
mediated signalling mechanisms appears to be implicated in 
the pathogenesis of a number of psychiatric disorders such 
as psychosis, depression, mania, and obsessive compul-
sive disorders (21,22). It is worth mentioning that acute or 
chronic stress decrease cell proliferation and neurogenesis, 
an effect reversed by antidepressants (23,24). In regards to 
the mechanism(s) through which antidepressants stimulate 
neurogenesis, the most convincing hypothesis suggests that 
antidepressants elicit such an effect by increasing the levels 
of neurotrophic factors such as BDNF (25). Long-term anti-
depressant treatment elevates both BDNF protein and mRN-
ABDNF levels and reverses stress-induced decrease in BDNF 
(26). Moreover, exogenous administration of BDNF displays 
antidepressant-like effects in animal models of depression 
(27). There are further reports suggesting the implication of 
BDNF in antidepressant action (28-34), however, few stud-
ies have measured NGF contents in multiple brain regions 
following the administration of psychotropic drugs and most 
of them have been limited in scope, examining a single drug 
class or brain region (35-37). In addition, the mechanism(s) 
by which psychotropic medications regulate NGF levels re-
mained elusive. This, has been recently studied in our labora-
tory which will be discussed in a later part of this paper.
Figure 1. Neurotrophic tysosine kinase receptors. As shown, tyrosine kinase receptors are a family of receptors with a similar 
structure. (Adapted from Nat Rev Mol Cell Bio 2003; 4: 46-55).
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FUNCTIONS AND THERAPEUTIC POTENTIALS OF NGF
The search for target-derived factors that support the survival 
and growth of motor and sensory neurons led Rita Levi-
Montalcini to the discovery of the first neurotrophin, NGF 
(reviewed in 38-40). Subsequent studies (41-47) showed that 
NGF (i) is synthesized and released by the target tissue of 
NGF-dependent axons and after binding to its receptors on 
axon terminals, is internalized and transported in a retrograde 
manner to the cell body, where it affects neuronal survival 
and differentiation, (ii) circulates throughout the body and is 
important for maintaining homeostasis, (iii) is critical for the 
memory and attention tasks that rely on the cholinergic sep-
tohippocampal pathway, (iv) exerts a modulatory role in the 
neuroendocrine-immune function, as well as inflammatory 
and neurological disorders, and (v) promotes peripheral nerve 
regeneration in an animal model of sciatic nerve injury. Be-
cause of its antioxidant, angiogenic, and insulinotropic prop-
erties, NGF may be implicated in the molecular mechanisms 
of cardiometabolic diseases including coronary atherosclero-
sis, obesity, type 2 diabetes, and metabolic syndrome (48,49). 
Moreover, NGF is involved in the suppression of food intake 
(50), and accelerating wound healing in skin and cornea ul-
cers (51-53). NGF produced and released by adipocytes and/
or mast cells may regulate the sympathetic innervation of 
adipose tissue. These may link adipose-derived NGF to the 
pathophysiology of both cardiometabolic and neuropsychiat-
ric diseases (54,55). Interestingly, treatment with nicergoline, 
an ergot alkaloid derivative with α1-adrenoreceptor-blocking 
and calcium antagonistic properties (56), has been shown to 
elevate the cerebral blood flow and improve the hemodynam-
ics in aged rats with cerebral ischemia (57). These effects 
appear to be linked to the nicergoline-induced NGF enhance-
ment in the aged rat brain (58). Therefore, the therapeutic 
potential of NGF in elderly individuals whose brain neurons 
are progressively dying with aging, merits further investiga-
tion. In recent years, NGF antagonism has been expected to 
be a highly effective therapeutic approach in acute or chronic 
pain states, and to be free of the adverse effects of traditional 
analgesic drugs (59). 
NGF AND NEUROPSYCHAITRIC DISEASES 
Experimental evidence suggests that antidepressant drugs 
and electroconvulsive treatment may act by enhancing cen-
tral nervous system (CNS) levels of neurotrophins. Accord-
ing to in vivo experiments, NGF has the capacity to increase 
circulating concentrations of adrenocorticotropin and cor-
ticosterone (60,61). In addition, in vitro experiments have 
shown that NGF is able to induce the release of hypothalamic 
vasopressin, a neuropeptide which plays a pivotal role in the 
formation of social bonding (62,63). Given these considera-
tions, it would be tempting to speculate that NGF is involved 
in the molecular mechanisms of emotions by acting as a fine 
modulator of distinct neuroendocrine functions. In this con-
text, the involvement of NGF in neuropsychiatric disorders 
such as dementia, depression, and schizophrenia has been 
reported (64-67). 
We have recently shown that a wide range of psycho-
tropic drugs including nortriptyline, isocarboxazid, citalo-
pram, risperidone and fluphenazine elevate NGF levels in 
dose-dependent and brain-region specific fashion (68,69). 
It is suggested that enhancement of NGF production may 
be specifically involved in the mechanisms of action of the 
antibipolar drugs such as lithium (70). However, lack of ef-
fects of antipsychotics including haloperidol, clozapine or 
olanzapine on BDNF or NGF levels in rat hippocampus has 
also been reported (71). It appears that differences in the ex-
perimental protocols, drug type, or dosing regimens might 
affect the study findings. Second-generation antipsychotics 
differ significantly with the first-generation antipsychotics in 
the regulation of brain NGF or BDNF levels, justifying the 
neurotrophin-mediated neuroprotection induced by the sec-
ond-generation antipsychotics. Meanwhile, more extended 
treatments with atypical antipsychotics may be associated 
with the reduction of neurotrophins (72). These findings may 
have important clinical implications for the optimal thera-
peutic management of neuropsychiatric disorders.
Antidepressants, NGF and neurokinin receptors
In recent years, the potential anxiolytic- and antidepres-
sant-like effects of compounds that target the neurokinin 
(NK) receptors, a class of G protein-coupled receptors 
which are found in the CNS and peripheral tissues, have 
attracted a growing interest. In this context, several selec-
tive and CNS-penetrating NK receptor antagonists which 
demonstrate efficacy in the treatment of emesis, anxiety, 
and depression have been synthesized (73-78). NK1, NK2, 
and NK3 receptors have been identified in both rodents and 
humans (79,80). The localization of NK receptors in the 
cortex, hippocampus, amygdala, and septum may be con-
sistent with the anxiolytic- and antidepressant-like effects 
of NK antagonists. As compared to the commonly used 
psychotropic medications, the effects of NK antagonists on 
neurotrophic factors are poorly characterized. There are a 
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few studies indicating the differential regulation of the NK1 
receptors and BDNF gene expression during inflammatory 
pain (81) or the increased levels of BDNF in NK1 receptor 
gene knockout mice (82). However, there is no previous re-
port linking the NK antagonists to NGF. We have recently 
investigated the potential involvement of NGF in the mech-
anisms of action of NK receptor antagonists. According to 
our findings, the selective NK receptor antagonists dose-de-
pendently elevate NGF levels in distinct brain regions rel-
evant to the regulation of mood including the frontal cortex 
(83). As previously reported, the frontal cortex is likely to 
be involved in depression and antidepressant medications 
block or reverse stress-induced pathogenic deficits in this 
brain area (84,85). The NK receptor antagonists can also el-
evate NGF concentration in the hippocampus which is sup-
posed to be indicative of their neuroprotective effects (83). 
NGF plays a critical role in the hippocampal plasticity and 
learning and regulates hippocampal neurogenesis, a process 
that is mediated by the antidepressant treatment (86). Fur-
thermore, NGF is involved in the cognitive function via the 
induction of acetylcholine release in the hippocampus (87). 
It is therefore reasonable to speculate that NK antagonists 
via enhancement of the hippocampal NGF improve psy-
chopathology and particularly cognitive performance. In 
a recently conducted study, the NK1 antagonist, N-acetyl-
L-tryptophan, improved the cognitive neurologic outcomes 
after traumatic brain injury (88). The potential mechanisms 
through which the NK antagonists exert neuroprotective ef-
fects are discussed (89). 
We have also shown the differential regulation of NGF 
levels by NK antagonists in the olfactory bulb and amygdala 
(83). NGF plays an essential role in the regeneration, mainte-
nance, and development of the olfactory system of mammals 
(90). In addition, NGF facilitates cholinergic neurotransmis-
sion between the nucleus basalis and amygdala which play 
an important role in the cognitive functions (91). As a whole, 
it appears that enhancement of the brain regional levelsof 
NGF constitutes an essential part of the biochemical altera-
tions induced by certain psychotropic medications including 
the NK receptor antagonists. 
To gain a mechanistic insight into the process by which 
psychotropic drugs regulate brain NGF levels, we have in-
vestigated the potential involvement of the endocannabonid 
system which is linked to depression and/or antidepressant 
effects (92), and appears to interact with neurotrophin signal-
ling (93-95). This, as well as other therapeutic potentials of 
the endocannabinoid system will be discussed herein. 
THE ENDOCANNABINOID SYSTEM 
The endocannabonid system refers to a group of neuromodu-
latory lipids and their receptors which are involved in a va-
riety of physiological processes including the regulation of 
motor activity, nociception, memory, appetite, temperature, 
brain development, and brain reward processes (96-99). The 
existence of an endogenous cannabinoid system was demon-
strated with the discovery of endogenous brain constituents, 
anandamide (N-arachidonoylethanolamine, AEA) and 2-ara-
chidonoylglycerol (2-AG), collectively termed the endocan-
nabinoids, which are synthesized on demand by neuronal 
cells. Endocannabinoids are not stored in the vesicles like 
other mediators and are inactivated through re-uptake and 
enzymatic hydrolysis in both neurons and astrocytes (Fig. 2) 
(100). They act as retrograde synaptic messengers (Fig. 3) 
and inhibit the release of different neurotransmitters in the 
hippocampus, cortex and striatum (101,102). Endocannabi-
noids are ligands for the cannabinoid receptors including the 
Figure 2. Inactivation of the endocannabinoids. Anandam-
ide and 2-Arachidonoylglycerol are internalized by neurons 
through a high-affinity transport (T) mechanism. Once inside 
cells, endocannabinoids are hydrolyzed by fatty acid amide 
hydrolase (FAAH). (Adapted from Curr Med Chem 2002; 9: 
663-676). 
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Figure 3. Model of hypothetical retrograde 
action of anandamide (AEA). (1) Presynaptic 
depolarization leads to calcium influx which in 
turn activates glutamate exocytosis. (2) Gluta-
mate diffuses through synaptic cleft and acti-
vates postsynaptic glutamate receptors. (3) Ac-
tivation of NMDA, AMPA and other glutamate 
subtype receptors leads to postsynaptic depo-
larization and calcium influx. (4) Elevated post-
synaptic calcium levels activate a transacylase 
(TA) which converts phosphatidylethanolamine 
(PE) into N-arachidonoylphosphatidyleth-
anolamine (NAPE). (5) NAPE is hydrolysed by 
a phospholipase D (PLD) which yields AEA. 
AEA is released from the postsynaptic cell and 
diffuses back to the presynaptic CB1 receptors. 
(6) Upon activation of the CB1 receptors by 
AEA, Gi/o-proteins are released which inhibit 
N-, and P/Q-type voltage-sensitive calcium 
channels. (7) Closing of voltage-sensitive cal-
cium channels results in a reduced release of 
neurotransmitters (8) (Adapted from Curr Med 
Chem 2002; 9: 663–676). 
CB1 and CB2, two G protein-coupled receptors primarily lo-
cated in the CNS and periphery, respectively (103). While 
the CB2 receptors are highly expressed in immune-compe-
tent cells, detectable levels of the CB1 receptors are found 
not only in central and peripheral neuronal cells, but also 
in a number of other cell types such as the immune cells, 
astrocytes, reproductive tissue cells, and endothelial cells 
in renal and vascular tissues. In the brain, the CB1 receptors 
are most abundant in the areas controlling motor, cognitive, 
emotional, and sensory functions, i.e., the hippocampus, 
basal ganglia, cerebellum, cortex, thalamus, amygdala, and 
olfactory bulb (104,105). During the last few years, the en-
docannabinoid system has emerged as a remarkable topic in 
the scientific community and many different regulatory ac-
tions both in the central and peripheral nervous systems have 
been attributed to the endocannabinoids. In this context, the 
synthesis of cannabinoid receptor agonists and antagonists, 
anandamide uptake blockers, and selective inhibitors of 
endocannabinoid degradation has triggered an exponential 
growth of studies (106,107). This has opened new strate-
gies in the treatment of pain, obesity, neurological diseases 
such as multiple sclerosis, and the emotional disturbances 
including depression and anxiety. Signal transduction and 
biological actions of endocannabinoids are summarized in 
Table 1.
THERAPEUTIC SIGNIFICANCE OF ENDOCANNABINOIDS
Endocannabinoids and analgesia
Even though non-steroidal anti-inflammatory drugs 
(NSAIDs) are widely used for their analgesic effects, the un-
derlying mechanism(s) are still puzzling. According to sev-
eral reports, NSAIDs probably act on targets other than the 
inhibition of cyclooxygenases to counteract pain (108). The 
discovery of endocannabinoid binding sites in the substan-
tia gelatinosa, an area involved with the transmission of pain 
signals, opened new insights into the nociception (109). In 
this context, antinociceptive effects of the endocannabinoids 
were reported in several pain models (110-112). Concomitant 
perfusion of the selective CB1 receptor antagonist, AM-251, 
reverses the antinociceptive activity of indomethacin, indi-
cating the involvement of CB1 receptors in the antinocicep-
tive activity of this NSAID (113). 
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Endocannabinoids and opioids 
The interaction between the endocannabinoids and opioids in 
treating pain has been extensively reviewed. It is worth men-
tioning that the endocannabinoids and opiates share a simi-
lar pharmacological profile. Both systems induce analgesia, 
hypothermia, sedation, hypotension, inhibition of intestinal 
motility and locomotor activity, changes in mood, and de-
pression of the immune function (114-117). Moreover, the 
mechanism by which the endocannabinoids produce antino-
ciception involves the release of spinal dynorphin (118). It 
is now well-established that opiates and endocannabinoids 
exhibit cross-tolerance and/or mutual potentiation for anti-
nociception after chronic treatment (119,120). It is suggested 
that the widespread reduction of the endocannabinoid 2-AG 
in the brain of morphine-tolerant rats accounts for the en-
hanced susceptibility to the neurodegenerative processes and 
premature aging following chronic exposure to morphine 
(121). A new insight into the molecular mechanisms of the 
crosstalk between the opiates and cannabinoids is further 
provided (122). 
Endocannabinoids and appetite 
Involvement of the endocannabinoid system in food-seeking 
behavior and obesity is well documented. Adipocytes appear 
to be a source of the endocannabonioids and related com-
pounds. This, may lead to the speculation that alipose tissue 
is implicated in the peripheral disregulation of the endocan-
nabinoid system during obesity (123). The endocannabinoid 
system has been suggested to act as a major mediator be-
tween brain, the alimentary system and the adipose tissue 
(124). Emerging data suggest that tetrahydrocannabinol acts 
via the CB1 receptors on hypothalamic nuclei and directly 
increases the appetite. In parallel, the hypothalamic neu-
rons tonically produce the endocannabinoids which regulate 
hunger (125). It is worth mentioning that endocannabinoid 
contents are inversely correlated with the amount of leptin 
in blood. For example, mice without leptin not only become 
massively obese, but have higher-than-normal levels of hy-
pothalamic endocannabinoids. Similarly, when these mice 
are treated with an endocannabinoid antagonist, food intake 
is reduced (126). Moreover, in CB1 receptor knock-out mice, 
the animals tend to be leaner and less hungry than wild-type 
mice (127). As aforementioned, the endocannabinoid system 
activate a pathway in the hypothalamus responsible for food-
seeking behavior, as well as endocannabinoids might also af-
fect the feeding behavior at the level of taste cells (128,129).
Endocannabinoids and reward system 
The presence of the endocannabinoid system in reward cir-
cuits and its role in motivational and emotional homeosta-
sis suggests that compounds which modulate cannabinoid 
signalling might serve as diagnostic or therapeutic tools in 
drug addiction. In accordance with this rationale, the CB1 
receptor antagonists have been shown to modulate opioid 
self-administration in rodents (130). Extending this hypoth-
esis, converging research lines have established a role for the 
endocannabinoids and CB1 receptors in alcohol dependence 
(131, 132). According to the findings of an animal study, 
chronic exposure to nicotine, ethanol, or cocaine induces a 
brain region-specific changes in the endocannabinoid con-
tents (133), therefore, it is likely that endocannabinoids me-
diate the anxiety-like symptoms induced by withdrawal from 
drugs of abuse.
Endocannabinoids and ischaemia-reperfusion injury
Ischaemia-reperfusion is a pivotal mechanism of organ in-
jury during stroke, myocardial infarction, organ transplan-
tation, and vascular surgery. There is a marked increase of 
endocannabinoid production in various forms of ischaemia-
reperfusion which correlate with the degree of tissue injury 
Biological actions:
Cortex, cerebellum and spinal cord
Blockade of N-methyl-D-aspartate (NMDA) receptors, 
control of tremor and spasticity.
Basal ganglia, striatum and globus pallidus
Control of psychomotor disorders, interference with 
dopamine transmission, inhibition of GABA-mediated 
transmission, induction of long-term depression, 
potentiation of GABA-mediated catalepsy.
Thalamus, hypothalamus and hippocampus
Control of pain initiation, control of wake–sleep cycles, 
control of thermogenesis, control of appetite and food 
intake, impairment of working memory, impairment 
of memory consolidation, inhibition of long-term 
potentiation, inhibition of glutamate-mediated 
transmission.
Retina
Control of scotopic vision
Table 1. Signal transduction and biological actions of 
endocannabinoids in the CNS
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and inflammation (134). Direct measurements usually con-
firm the increase of target tissue endocannabinoid levels fol-
lowing preconditioning. The involvement of the CB1/CB2 
receptors may be determined by using knockout mice (135). 
Endocannabinoids and reproduction
The role of the endocannabinoids in female reproduction is 
an emerging concept. In embryo implantation timing, the 
endocannabinoid system plays an important regulatory role 
(136). Cannabinoid receptors are expressed by the devel-
oping embryo and are responsive to the uterine anandam-
ide which modulates the probability of implantation to the 
uterine wall (137). The likelihood of human miscarriage is 
increased if uterine anandamide levels are too high or low 
(138). These findings suggest that proper intake of exoge-
nous cannabinoids can decrease the likelihood for pregnancy 
for women with high anandamide levels, and alternatively, it 
can increase the likelihood for pregnancy in women whose 
anandamide levels are too low. 
Endocannabinoids and cytotoxicity
Since the first reference on antineoplastic action of endocan-
nabinoids on lung adenocarcinoma and leukemia cells, there 
has been increasing evidence about the cytotoxic, proapop-
totic and antineoplastic effects of endocannabinoids in vivo 
and in vitro (139,140). Mitogen-activated protein kinase 
(MAPK)-dependent signaling, ceramide, oxidative stress, 
and lipid rafts appear to be involved in the triggering of ap-
optosis by the endocannabinoids (141). These authors repre-
sented the cannabinoids as potential anticancer agents either 
solo or in combination with other cancerostatics. 
Endocannabinoids and neuroprotection
Regardless of the point of initiation, the neurotoxic events 
Figure 4. Roles of the endocannabinoids in long-term synaptic plasticity. a) Repetitive activation of corticostriatal fibres 
causes a persistent reduction of glutamate release, called long-term depression (LTD) which might be mediated by anandamide 
(AEA). The elevated Ca2+ concentrations produced in postsynaptic spines of striatal medium spiny neurons after the stimulation 
could trigger anandamide formation which in turn might induce LTD by engaging CB1 cannabinoid receptors on glutamatergic 
axon terminals. b) High-frequency stimulation of glutamatergic Schaffer collaterals in the hippocampus elicits a prolonged 
reduction of GABA (γ-aminobutyric acid) release that might be mediated by 2-arachidonoylglycerol (2-AG). This heterosynap-
tic form of plasticity, called inhibitory-LTD (I-LTD) is induced when glutamate activates metabotropic receptors (mGluR) on 
pyramidal neurons, eliciting 2-AG formation through the diacylglycerol lipase (DGL) pathway. 2-AG might then travel sideways 
to engage the CB1 receptors on contiguous terminals of GABA interneurons, producing I-LTD. (Adapted from Nat Rev Neurosci 
2003; 4: 873-884).
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self-amplify and ultimately lead to cell death (142). A unique 
opportunity to improve inflammation and neurodegeneration 
simultaneously might be offered by pharmacological agents 
that can modulate the activity of cannabinoid receptors (143). 
In animal model of brain injury, the neuroprotective action of 
the endocannabinoid 2-AG has been reported (144). In the 
experimental models of Alzheimer’s disease, stimulation of 
either CB1 or CB2 receptor subtypes prevents microglial ac-
tivation, microglia-mediated neurotoxicity, and neurodegen-
eration (145). The therapeutic potential of the cannabinoid 
receptor agonist WIN55212-2 against nigrostriatal degen-
eration is demonstrated (146). Degeneration of dopaminergic 
neurons during the experimental Parkinson’s disease may be 
reduced by the agonists of CB1 or CB2 receptors (147). A link 
between the endocannabinid signalling in the globus pallidus 
and symptoms of the disease has been reported (148). More-
over, pharmacological agonists of cannabinoid receptors ex-
ert beneficial effects in amyotrophic lateral sclerosis (149). 
 In recent years, a growing interest has been attracted to-
wards the therapeutic potentials of endocannabinoids in mul-
tiple sclerosis (MS). According to the historical records from 
ancient China and Greece, the preparations of Cannabis Indi-
ca were commonly prescribed to ameloriate MS-like symp-
toms such as tremors and muscle pain (150). Afterwards, 
cannabis-based medicine were used for the treatment of MS. 
Due to the illegality of cannabis and rising number of MS 
patients undergoing self-medication, there has been much in-
terest in exploiting the endocannabinoid system to provide a 
legal and effective relief (151). In the experimental models 
of MS, stimulation of either CB1 or CB2 receptors has been 
beneficial against the inflammatory process (152). In mouse 
models of MS, a profound reduction and reorganization of 
the CB1 receptors has been observed in the cerebellum (153). 
CB1 agonists promote both in vitro survival of oligodendro-
cytes and mRNA expression of myelin lipid protein (154). 
Moreover, the endocannabinoid 2-AG has been shown to 
stimulate proliferation of a microglial cell line through a CB2 
receptor-dependent mechanism (155). Taken together, these 
studies point to the exciting possibility that cannabinoid 
treatment may not only be able to attenuate the symptoms of 
MS, but also improve oligodendrocyte function. Despite the 
potential benefits of drugs acting on the cannabinoid recep-
tors, their clinical use is hampered mainly because of their 
psychotropic effects (156). Therefore, designing cannabinoid 
derivatives devoid of psychoactive side effects appears to be 
helpful in the management of the debilitating disease, MS.
 In general, cannabinoids exert their neuroprotective re-
sponses through activation of the cannabinoid receptors 
(157,158). However, cannabinoids may also protect neu-
rons independent of the cannabinoid receptors. For example, 
WIN55, 212-2 may protect cerebral cortical neurons from 
in vitro hypoxia and glucose deprivation in a cannabinoid 
receptor-independent manner (159). Moreover, exogenous 
anandamide and 2-AG have been shown to protect cultured 
cerebral neurons against the toxic levels of the ligands of 
glutamate, AMPA, and kainate receptors in a cannabioid 
receptor-independent fashion (160). 
 The mechanisms through which the exogenous cannab-
inoids exert neuroprotection in a variety of in vitro and in 
vivo models of neuronal injury include: (i) prevention of the 
excitotoxicity through the CB1 receptor-mediated inhibition 
of glutamate transmission. This, is performed by closing the 
N- and P/Q-type Ca2+ channels (161), (ii) reduction of Ca2+ 
influx at both pre- and postsynaptic levels followed by in-
hibition of subsequent noxious cascades (162), (iii) antioxi-
dant activity mainly owing to the phenol group of various 
resorcinol-type cannabinoids (163), (iv) suppression of the 
production of tumor necrosis factor-α (164), (v) activation 
of the phosphatidylinositol 3-kinase/protein kinase B path-
way (165), (vi) induction of phosphorylation of extracellular 
regulated kinases (166), and (vii) induction of the expression 
of transcription factors and neurotrophins (167). 
Endocannabinoids and mood disorders
As aforementioned, mood disorders represent a chronic de-
bilitating disease group that are highly prevalent worldwide 
(1). Among all mental disorders, major depression has the 
highest rate of prevalence and incidence of morbidity. Drugs 
that directly influence the availability of brain monoamines, 
are considered as the primary medical treatment of depres-
sion (2). Unfortunately, the currently available antidepres-
sant therapies have limited efficacies. Consequently, the re-
search on new drugs for the treatment of mood disorders has 
become increasingly critical. Compelling evidence suggests 
that compounds which affect the endocannabinoid signalling 
not only modulate monoamine-mediated neurotransmission, 
but also affect the activity of the hypothalamic–pituitary–ad-
renal (HPA) axis (168). We have shown that activation of the 
endocannabinoid system is necessary for the suppression of 
HPA axis activity by tricyclic antidepressant doxepin (169). 
Recent preclinical evidences indicating the important roles of 
cannabinoid agonists or endocannabinoid enhancers (e.g. the 
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fatty acid amide hydrolase (FAAH) inhibitors) in the regula-
tion of mood, have opened a new line of research in antide-
pressant drug discovery (170). Endocannabinoids are present 
in moderate to high levels in limbic brain regions including 
the prefrontal cortex, hippocampus, and amygdala, where the 
neuronal activity is altered in depression (171). Deficiencies 
in the endocannabinoid signaling are associated with a be-
havioral phenotype similar to the symptom profile of severe 
depression (172). In this context, several pharmacological 
and somatic treatments against depression have been shown 
to increase the endocannabinoid neurotransmission which, 
in some cases, is required for the neurobiological adapta-
tions elicited by these treatments (173). Cannabinoids and 
the related compounds may also exert a therapeutic potential 
in anxiety-related disorders (174). Patients treated with can-
nabinergic compounds for MS or chronic neuropathic pain, 
might also benefit from the anxiolytic effects of the canna-
bionids (175). Studies in animal models have shown that the 
CB1 receptor antagonist SR141716A induces anxiety-like 
responses (176). Meanwhile, psychoactive cannabinoids 
are able to induce both anxiolytic and anxiety-like reactions 
which are dose- and context-dependent (177). 
 The neurobiological mechanism(s) linking the endocan-
nabinoid system with the pathophysiology of mood disorders 
and antidepressant action have remained somewhat elusive. 
Similar to the actions of conventional antidepressants, acti-
vation of the endocannabinoid signalling may result to the 
enhancement of serotonergic and noradrenergic transmis-
sion, cellular plasticity, and neurotrophin expression within 
the hippocampus (178, 179). We have shown that chronic 
exposure to a wide range of psychotropic medications in-
cluding the NK receptor antagonists induce a significant el-
evation of both endocannabinoids anandamide and 2-AG in 
the brain regions which are implicated in the regulation of 
emotional behaviour and synaptic plasticity (69,83). These 
findings suggest an existence of intrinsic endocannabinoid 
activity that contributes to the mechanisms of action of cer-
tain psychotropic drugs. In general, brain regional distribu-
tion of endocannabinoids following psychotropic treatment 
suggests that cannabinoid system may be integral to the de-
velopment and maintenance of effective coping strategies to 
the emotional responses as well as achievement a better drug 
efficacy. 
 In our studies, endocannabinoid contents were increased 
within the brain regions in which psychotropic drugs were 
also able to elevate NGF production. Furthermore, CB1 re-
ceptor neutral antagonist, AM4113, by blocking endogenous 
cannabinoid activity prevented psychotropic-induced en-
hancement of NGF (69,83). These findings argue for CB1-
mediated up-regulation of central NGF by psychotropic 
medications and are in agreement with previous reports sug-
gesting an interaction between the endocannabinoid system 
and neurotrophins (93-95).
CONCLUSION
During the last few years, the increasing interest in the en-
docannabinoid system which is involved in the regulation of 
many cellular and physiological functions, has led to a number 
of interesting data derived from animal studies. Our recent 
findings demonstrate that the endocannabinoid system plays a 
pivotal role in the action of currently used psychotropic medi-
cations including the regulation of the HPA axis activity and 
brain regional levels of NGF. These findings may present an 
impetus for a better understanding of the complex scenario of 
the cannabinoid effects in humans as well as the pathophysi-
ological mechanisms underlying neuropsychiatric disorders. 
Now, the time has arrived for clinical researchers to look at 
the cannabinoid system as a valuable target for drug discov-
ery, especially in disorders for which no effective therapeu-
tic or prophylactic regimens are presently available. As Eden 
Phillpotts (1862-1960) wrote, “The universe is full of magical 
things patiently waiting for our wits to grow sharper.”
REFERENCES
1.  Kessler RC, Berglund P, Demler O, Jin R, Koretz D, 
Merikangas KR, et al. The epidemiology of major de-
pressive disorder. JAMA 2003; 289(23): 3095–3105. 
2.  Ressler KJ, Nemeroff CB. Role of serotonergic and no-
radrenergic systems in the pathophysiology of depres-
sion and anxiety disorders. Depress Anxiety 2000; 12: 
2–19.
3.  Holsboer F. The corticosteroid receptor hypothesis of 
depression. Neuropsychopharmacology 2000; 23: 477–
501. 
4.  McEwen BS. Glucocorticoids, depression, and mood 
disorders: structural remodeling in the brain. Metabo-
lism 2005; 54: 20–23. 
5.  Lu XY. The leptin hypothesis of depression: a potential 
link between mood disorders and obesity? Curr Opin 
Pharmacol 2007; 7: 648–652.
6.  Gertler A. Role of leptin in early metabolic program-
ming. Adipobiology 2009; 1: 27-34.
40
Biomed Rev 21, 2010
Hassanzadeh
7.  Bun-Hee L, Aye-Mu M, Yong-Ku K. Psychotropic drugs 
on in vitro brain-derived neurotrophic factor production 
in whole blood cell cultures from healthy subjects. J 
Clin Psychopharm 2010; 30: 623-627.
8.  Manji HK, Moore GJ, Rajkowska G, Chen G. Neuro-
plasticity and cellular resilience in mood disorders. Mol 
Psychiatry 2000; 5: 578-593.
9. Reichardt LF. Neurotrophin-regulated signalling path-
ways. Philos Trans R Soc Lond B Biol Sci 2006; 361: 
1545–1564.
10.  Allen SJ, Dawbarn D. Clinical relevance of the neuro-
trophins and their receptors. Clin Sci 2006; 110: 175–
191.
11.  Greene LA, Kaplan DR. Early events in neurotrophin 
signaling via Trk and p75 receptors. Curr Opin Neuro-
biol 1995; 5: 579–587.
12.  Gallo G, Letourneau PC. Localized sources of neuro-
trophins initiate axon collateral sprouting. J Neurosci 
1998; 18: 5403–5414.
13.  McAllister AK, Lo DC, Katz LC. Neurotrophins regu-
late dendritic growth in developing visual cortex. Neu-
ron 1995; 15: 791–803.
14. Song HJ, Ming GL, Poo MM. A cAMP-induced witch-
ing of turning direction of nerve growth cones. Nature 
1997; 388: 275–279.
15. Lesser SS, Sherwood NT, Lo DC. Neurotrophins differ-
entially regulate voltage-gated ion channels. Mol Cell 
Neurosci 1997; 10: 173–183.
16. Lohof AM, Ip NY, Poo MM. Potentiation of developing 
neuromuscular synapses by the neurotrophins NT-3 and 
BDNF. Nature 1993; 363: 350–353. 
17. Kang H, Schuman EM. Long-lasting neurotrophin-
induced enhancement of synaptic transmission in the 
adult hippocampus. Science 1995; 267: 1658–1662.
18. Hans T. Neurotrophins and neuronal plasticity. Science 
1995; 270: 593-598.
19. Poo MM. Neurotrophins as synaptic modulators. Nat 
Rev Neurosci 2001; 2: 24-32. 
20. Schulte-Herbrüggen O, Jockers-Scherübl MC, Hellweg 
R. Neurotrophins: from pathophysiology to treatment in 
Alzheimer’s disease. Curr Alzheimer Res 2008; 5: 38-
44.
21. Shaltiel G, Chen G, Manji HK. Neurotrophic signaling 
cascades in the pathophysiology and treatment of bipo-
lar disorder. Curr Opin Pharmacol 2007; 7: 22-26.
22. Pacher P, Kohegyi E, Kecskemeti V, Furs S. Current 
trends in the development of new antidepressants. Curr 
Med Chem 2001; 8: 89-100. 
23. Vaida VA, Duman RS. Depression: emerging insights 
from neurobiology. Br Med Bull 2001; 57: 61-79.
24. Warner-Schmidt JL, Duman RS. Hippocampal neuro-
genesis: opposing effects of stress and antidepressant 
treatment. Hippocampus 2006; 16: 239-249.
25. Dias BG, Banerjee SB, Duman RS, Vaidya VA. Differ-
ential regulation of brain derived neurotrophic factor 
transcripts by antidepressant treatments in the adult rat 
brain. Neuropharmacology 2003; 45: 553-563.
26.  Nibuya M, Morinobu S, Duman RS. Regulation of 
BDNF and Trkb mRNA in rat brain by chronic electro-
convulsive seizure and antidepressant drug treatment. J 
Neurosci 1995; 15: 7539-7547. 
27. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Du-
man RS. Brain-derived neurotrophic factor produces 
antidepressant effects in behavioural models of depres-
sion. J Neurosci 2002; 22: 3251-3261.
28. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-
derived neurotrophic factor in mood disorders. Brain 
Res Brain Res Rev 2004; 45: 104-114.
29. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy 
G, Aubry JM. Decreased serum brain-derived neuro-
trophic factor levels in major depressed patients. Psy-
chiatry Res 2002; 109: 143-148.
30. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, 
Young LT. Increased hippocampal BDNF immunoreac-
tivity in subjects treated with antidepressant medication. 
Biol Psychiatry 2001; 50: 260-265.
31. Shimizu E, Hashimoto K, Okamura N, Koike K, Ko-
matsu N, Kumakiri C, et al. Alterations of serum lev-
els of brain-derived neurotrophic factor (BDNF) in de-
pressed patients with or without antidepressants. Biol 
Psychiatry 2003; 54: 70-75.
32. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Anti-
depressant-like effect of brain-derived neurotrophic fac-
tor (BDNF). Pharmacol Biochem Behav 1997; 56: 131-
137.
33. Altar CA, Whitehead RE, Chen R, Wortwein G, Mad-
sen TM. Effects of electroconvulsive seizures and anti-
depressant drugs on brain-derived neurotrophic factor 
protein in rat brain. Biol Psychiatry 2003; 54: 703-709.
34. Van Hoomissen JD, Chambliss HO, Holmes PV, Dish-
man RK. Effects of chronic exercise and imipramine 
on mRNA for BDNF after olfactory bulbectomy in rat. 
Brain Res 2003; 974: 228-235.
35. Alvin V, Terry J, Debra A, Warner GS, Hohnadel EJ, 
Middlemore ML, et al. Protracted effects of chronic 
oral haloperidol and risperidone on nerve growth fac-
41
Biomed Rev 21, 2010
Endocannabinoids, neurotrophins, psychotropic drugs 
tor, cholinergic neurons, and spatial reference learning 
in rats. Neuroscience 2007; 150: 413-424. 
36. Angelucci F, Aloe L, Gruber SHM, Fiore M, Mathé AA. 
Chronic antipsychotic treatment selectively alters nerve 
growth factor and neuropeptide Y immunoreactivity and 
the distribution of choline acetyl transferase in rat brain 
regions. Int J Neuropsychopharm 2000; 3: 13-25. 
37. Vinay P, KhanMohammad M, Alvin T, Sahebarao PM. 
Differential effects of typical and atypical antipsychot-
ics on nerve growth factor and choline acetyltransferase 
expression in the cortex and nucleus basalis of rats. J 
Psychiat Res 2004; 38: 521-529.
38. Levi-Montalcini R. The nerve growth factors 35 years 
later. Science 1987; 237: 1154-1162.
39. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, 
Leon A. Nerve growth factor: from neurotrophin to neu-
rokine. Trends Neurosci 1996; 19: 514-520. 
40. Levi-Montalcini R. The nerve growth factor and the 
neuroscience chess board. Prog Brain Res 2004; 146: 
525–527.
41. Ebendal T. Function and evolution in the NGF family 
and its receptors. J Neurosci Res 1992; 32: 461-470.
42. Lad SP, Neet KE, Mufson EJ. Nerve growth factor: 
structure, function and therapeutic implications for 
Alzheimer’s disease. Curr Drug Targets CNS Neurol 
Disord 2003; 2: 315-334.
43. Arredondo LR, Deng C, Ratts RB, Lovett-Racke AE, 
Holtzman DM, Racke MK. Role of nerve growth factor 
in experimental autoimmune encephalomyelitis. Eur J 
Immunol 2001; 31: 625-633.
44. Aloe L, Tirassa P, bracci-Laudiero L. Nerve growth fac-
tor in neurological and non neurological diseases: Ba-
sic findngs and emerging pharmacological prospective. 
Curr Pharmacol Design 2001; 7: 113-123.
45. Tuveri M, Generine S, Matucci-Cenerini M, Aloe L. 
Nerve growth factor, a useful tool in the treatment of 
chronic vasculitis ulcers in rheumatoid arthritis. Lancet 
2000; 356: 1739-1740. 
46. Fiore M, Chaldakov GN, Aloe L. Nerve growth factor 
as a signalling molecule for nerve cells and also for the 
neuroendocrine-immune systems. Rev Neurosci 2009; 
20: 133-145. 
47.  Sun W, Sun C, Lin H, Zhao H, Wang J, Ma H, et al. The 
effect of collagen-binding NGF-beta on the promotion 
of sciatic nerve regeneration in a rat sciatic nerve crush 
injury model. Biomaterials 2009; 30: 4649–4656.
48.  Chaldakov GN, Fiore M, Stankulov IS, Manni L, Hris-
tova MG, Antonelli A, et al. Neurotrophin presence 
in human coronary atherosclerosis and metabolic syn-
drome: a role for NGF and BDNF in cardiovascular dis-
ease? Prog Brain Res 2004; 146: 279–289.
49. Chaldakov GN, Fiore M, Tonchev AB, Dimitrov D, 
Pancheva R, Rancic G, et al. Homo obesus: a metab-
otrophin-deficient species. Pharmacology and nutrition 
insight. Curr Pharm Des 2007; 13: 2176-2179.
50. Lapchak PA, Araujo DM. NGF suppression of weight 
gain in adult female rats correlates with decreased hy-
pothalamic cholecystokinin levels. Brain Res 1994; 
655: 12-16.
51. Kawamoto K, Matsuda H. Nerve growth factor and 
wound healing. Prog Brain Res 2004; 146: 369-84.
52. Tuveri MA, Triaca V, Aloe L. The nerve growth fac-
tor induces cutaneous ulcer healing in “non-responder” 
tranplanted skin. Ann Ist Super Sanita 2006; 42: 94-96.
53. Lambiase A, Manni L, Rama P, Bonini S. Clinical ap-
plication of nerve growth factor on human corneal ulcer. 
Arch Ital Biol 2003; 141: 141-148.
54. Sornelli F, Fiore M, Chaldakov GN, Aloe L. Adipose 
tissue-derived nerve growth factor and brain-derived 
neurotrophic factor: results from experimental stress 
and diabetes. Gen Physiol Biophys 2009; 28: 179-183. 
55. Chaldakov GN, Tonchev AB, Aloe L. NGF and BDNF: 
from nerves to adipose tissue, from neurokines to me-
tabokines. Relevance to neuropsychiatric and cardi-
ometabolic diseases. Riv Psichiatr 2009; 44: 79-87.
56. Heitz C, Descombes JJ, Miller RC, Stoclet JC. 
α-adrenoceptor antagonistic and calcium antagonistic 
effects of nicergoline in the rat isolated aorta. Eur J 
Pharmacol 1986; 123: 279-185.
57. Takahashi K, Akaike N. Nicergoline inhibits T-type 
Ca2+ channels in rat hipppocampal CA1 pyramidal neu-
rons. Br J Pharmacol 1990; 100: 705-710.
58. Nishio T, Sunohara N, Furukawa S, Akiguchi I, Kudo 
Y. Repeated injections of nicergoline increase the nerve 
growth factor level in the aged rat brain. Jpn J Pharma-
col 1998; 76: 321-323.
59. Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, 
Shelton DL, et al. Novel class of pain drugs based on 
antagonism of NGF. Trends Pharmacol Sci 2006; 27: 
85-91. 
60.  Otten U, Baumann JB, Girard J. Stimulation of the pitu-
itary-adrenocortical axis by nerve growth factor. Nature 
1979; 282: 413-414.
61.  Enzo E, Pierluigi P, Marika B, Piercarlo M, Marco B, 
Diego G. Raised plasma nerve growth factor levels as-
sociated with early-stage romantic love. Psychoneu-
42
Biomed Rev 21, 2010
Hassanzadeh
roendocrinology 2006; 31(3): 288-294.
62.  Lim MM, Young LJ. Neuropeptidergic regulation of af-
filiative behavior and social bonding in animals. Horm 
Behav 2006; 50: 506–517.
63. Kendrick KM. The neurobiology of social bonds. J Neu-
roendocrinol 2004; 16: 1007–1008.
64. Angelucci F, Aloe L, Vasquez PJ, Mathe AA. Mapping 
the differences in the brain concentration of brain-de-
rived neurotrophic factor (BDNF) and nerve growth 
factor (NGF) in an animal model of depression. Neu-
roreport 2000; 11(6): 1369-1373.
65. Chaldakov GN, Tonchev A, Aloe L. NGF and BDNF: 
from nerves to adipose tissue, from neurokines to me-
tabokines. Relevance to neuropsychiatric and cardi-
ometabolic. Riv Psichiatr 2009; 44: 79-87.
66. Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve 
growth factor in never-medicated first-episode psychot-
ic and medicated chronic schizophrenic patients: pos-
sible implications for treatment outcome. Schizophr Res 
2003; 60: 117-123.
67. Alleva E, Petruzzi S, Cirulli F, Aloe L. NGF regulatory 
role in stress and coping of rodents and humans. Phar-
macol Biochem Behav 1996; 54: 65-72.
68. Hassanzadeh P, Hassanzadeh A. Effects of different 
psychotropic agents on the central nerve growth factor 
protein. Iran J Basic Med Sci 2010; 13: 202-209.
69. Hassanzadeh P, Rahimpour S. The cannabinergic sys-
tem is implicated in the upregulation of central NGF 
protein by psychotropic drugs. Psychopharmacology 
2010; (doi 10.1007/s00213-010-2120-4, Epub ahead of 
print).
70. Hellweg R, Lang UE, Nagel M, Baumgartner A. 
Subchronic treatment with lithium increases nerve 
growth factor content in distinct brain regions of adult 
rats. Mol Psychiatry 2002; 7: 604-608.
71. Valvassori SS, Stertz L, Andrezza AC, Rosa MI, Kapc-
zinski F, Streck EL, et al. Lack of effect of antipsychot-
ics on BDNF and NGF levels in the hippocampus of rat. 
Metab Brain Dis 2008; 23: 213-219.
72.  Pillai A, Terry Jr. AV, Mahadik SP. Differential effects 
of long-term treatment with typical and atypical antip-
sychotics on NGF and BDNF levels in rat striatum and 
hippocampus. Schizophr Res 2006; 82: 95-106.
73.  Dableh LJ, Yashpal K, Rochford J, Henry JL. Antide-
pressant-like effects of neurokinin receptor antagonists 
in the forced swim test in the rat. Eur J Pharmacol 2005; 
507: 99-105.
74. Griebel G, Perrault G, Soubrié P. Effects of SR48968, a 
selective non-peptide NK2 receptor antagonist on emo-
tional processes in rodents. Psychopharmacology 2001; 
158: 241-251.
75. Salomé N, Stemmelin J, Cohen C, Griebel G. Selective 
blockade of NK2 or NK3 receptors produces anxiolyt-
ic- and antidepressant-like effects in gerbils. Pharmacol 
Biochem Behav 2006; 83: 533-539.
76. Varty GB, Cohen-Williams ME, Morgan CA, Pylak 
U, Duffy RA, Lachowicz JE, et al. The gerbil elevated 
plus-maze II: anxiolytic effects of selective neurokinin 
NK1 receptor antagonists. Neuropsychopharmacology 
2002; 27: 372-379.
77. Varty GB, Cohen-Williams ME, Hunter JC. The antide-
pressant-like effects of neurokinin NK1 receptor antag-
onists in a gerbil tail suspension test. Behav Pharmacol 
2003; 14: 87-95.
78. Zocchi A, Varnier G, Arban R, Griffante C, Zanetti L, 
Bettelini L, et al. Effects of antidepressant drugs and GR 
205171, an neurokinin-1 (NK1) receptor antagonist, on 
the response in the forced swim test and on monoamine 
extracellular levels in the frontal cortex of the mouse. 
Neurosci Lett 2003; 345: 73-76.
79. Bensaid M, Faucheux BA, Hirsch E, Agid Y, Soubrie P, 
Oury-Donat F. Expression of tachykinin NK2 receptor 
mRNA in human brain. Neurosci Lett 2001; 303: 25-28.
80. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto 
FM, Maggi CA. Tachykinins and tachykinin receptors: 
a growing family. Life Sci 2004; 74: 1445-1463.
81. Duric V, McCarson KE. Neurokinin-1 (NK-1) recep-
tor and brain-derived neurotrophic factor (BDNF) gene 
expression is differentially modulated in the rat spinal 
dorsal horn and hippocampus during inflammatory pain. 
Mol Pain 2007; 3: 32.
82. Morcuende S, Gadd CA, Peters M, Moss A, Harris EA, 
Sheasby A, et al. Increased neurogenesis and brain-de-
rived neurotrophic factor in neurokinin-1 receptor gene 
knockout mice. Eur J Neurosci 2003; 18: 1828-1836. 
83.  Hassanzadeh P, Hassanzadeh A. Involvement of the 
cannabinoid and neurotrophin systems in the mecha-
nisms of action of neurokinin receptor antagonists. Eur 
Neuropsychopharmacol 2011 (in press). 
84. Banasr M, Valentine GW, Li XY, Gourley SL, Taylor 
JR, Duman RS. Chronic unpredictable stress decreases 
cell proliferation in the cerebral cortex of the adult rat. 
Biol Psychiat 2007; 62: 496-504.
85. Duman R. Depression: A case of neuronal life and 
death? Biol Psychiatry 2004; 56: 140-145.
86. Conner JM, Franks KM, Titterness AK, Russell K, Mer-
43
Biomed Rev 21, 2010
Endocannabinoids, neurotrophins, psychotropic drugs 
rill DA, Christie BR, et al. NGF is essential for hip-
pocampal plasticity and learning. J Neurosci 2009; 29: 
10883-10889.
87. Winkler J, Ramirez GA, Thal LJ, Waite JJ. Nerve 
growth factor (NGF) augments cortical and hippocam-
pal cholinergic functioning after p75NGF receptor-me-
diated deafferentation but impairs inhibitory avoidance 
and induces fear-related behaviors. J Neurosci 2000; 
20(2): 834-844.
88. Donkin JJ, Nimmo AJ, Cernak I, Blumbergs PC, Vink, 
R. Substance P is associated with the development of 
brain edema and functional deficits after traumatic brain 
injury. J Cereb Blood Flow Metab 2009; 29: 1388-1398. 
89. Vink R, Nimmo AJ, Cernak I. An overview of new and 
novel pharmacotherapies for use in traumatic brain in-
jury. Clin Exp Pharmacol Physiol 2001; 28: 919-921. 
90. Miwa T, Moriizumi T, Horikawa I, Uramoto N, Ishima-
ru T, Nishimura T, et al. Role of nerve growth factor in 
the olfactory system. Microsc Res Tech 2002; 58: 197-
203.
91. Moises HC, Womble MD, Washburn MS, Williams LR. 
Nerve growth factor facilitates cholinergic neurotrans-
mission between nucleus basalis and the amygdala in 
rat: an electrophysiological analysis. J Neurosci 1995; 
15: 8131-8142.
92. Bambico FR, Duranti A, Tontini A, Tarzia G, Gobbi G. 
Endocannabinoids in the treatment of mood disorders: 
evidence from animal models. Curr Pharm Design 
2009; 15: 1623-1646.
93. Aso E, Ozaita A, Valdiza´n EM, Ledent C, Pazos A, 
Maldonado R. BDNF impairment in the hippocampus is 
related to enhanced despair behavior in CB1 knockout 
mice. J Neurochem 2008; 105: 565-572.
94. Williams EJ, Walsh FS, Doherty P. The FGF receptor 
uses the endocannabinoid signaling system to couple to 
an axonal growth response. J Cell Biol 2003; 160: 481-
486.
95. Lemtiri-Chlieh F, Levine ES. BDNF evokes release of 
endogenous cannabinoids at layer 2/3 inhibitory synaps-
es in the neocortex. J Neurophysiol 2010; 285: 19002-
19011.
96. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. En-
docannabinoids: endogenous cannabinoid receptor lig-
ands with neuroremodulatory action. Trends Neurosci 
1998; 21: 521–528.
97. Ferna´ndez-Ruiz JJ, Berrendero F, Herna´ndez ML, Ra-
mos JA. The endogenous cannabinoid system and brain 
development. Trends Neurosci 2000; 23: 14-20.
98. Hungund BL, Basavarajappa BS. Are anandamide and 
cannabinoid receptors involved in ethanol tolerance? A 
review of the evidence. Alcohol Alcohol 2000; 35: 126–
133.
99. Yamamoto T, Takada K. Role of cannabinoid receptors 
in the brain as it relates to drug reward. Jpn J Pharmacol 
2000; 84: 229–236.
100. Di Marzo V. Endocannabinoids and other fatty acid de-
rivatives with cannabimimetic properties: biochemistry 
and possible physiopathological relevance. Biochim 
Biophys Acta 1998; 1392: 153–175.
101. Wilson RI, Kunos G, Nicoll RA. Presynaptic specifi-
city of endocannabinoid signalling in the hippocampus. 
Neuron 2001; 31: 453–462.
102. Wilson RI, Nicoll RA. Endogenous cannabinoids medi-
ate retrograde signalling at hippocampal synapses. Na-
ture 2001; 410: 588–592. 
103. Hanus L, Gopher A, Almog S, Mechoulam R. Two new 
unsaturated fatty acid ethanolamides in brain that bind 
to the cannabinoid receptor. J Med Chem 1993; 36: 
3032–3034.
104. Redmer A, Kathmann M, Eberhard S. Cannabinoid CB1 
receptor-mediated inhibition of hippocampal acetylcho-
line release is preserved in aged mice. Br J Pharmacol 
2003; 138: 1425–1430. 
105. Pertwee RG. Pharmacology of cannabinoid CB1 and 
CB2 receptors. Pharmacol Ther 1997; 74: 129–180.
106. Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, 
Miyauchi H, et al. Exceptionally potent inhibitors of 
fatty acid amide hydrolase: the enzyme responsible for 
degradation of endogenous oleamide and anandamide. 
Proc Natl Acad Sci USA 2000; 97: 5044–5049.
107. Casanova ML, Blazquez C, Martinez-Palacio J, Vil-
lanueva C, Fernandez-Acenero MJ, Huffman JW, et 
al. Inhibition of skin tumor growth and angiogenesis in 
vivo by activation of cannabinoid receptors. J Clin In-
vest 2003; 111: 43–50.
108. Brune K, Beck WS, Geisslinger G, Menzel-Soglowek 
S, Peskar BM, Peskar BA. Aspirin-like drugs may block 
pain independently of prostaglandin synthesis inhibi-
tion. Experientia 1991; 47: 257– 261.
109. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de 
Costa BR, Rice KC. Characterization and localization 
of cannabinoid receptors in rat brain: a quantitative in 
vitro autoradiographic study. J Neurosci 1991; 11: 563–
583.
110. Pertwee RG. Cannabinoid receptors and pain. Prog 
Neurobiol 2001; 63: 569–611.
44
Biomed Rev 21, 2010
Hassanzadeh
111. Calignano A, La Rana G, Giuffrida A, Piomelli D. Con-
trol of pain initiation by endogenous cannabinoids. Na-
ture 1998; 394: 277–281.
112. Calignano A, La Rana G, Loubet-Lescoulie P, Piomelli 
D. A role for the endogenous cannabinoid system in the 
peripheral control of pain initiation. Prog Brain Res 
2000; 129, 471–482.
113. GÜhring H, Hamza M, Sergejeva M, Ates M, Kotalla 
CE, Ledent C. A role for endocannabinoids in indometh-
acin induced spinal antinociception. Eu J Pharmacol 
2002; 454: 153–163.
114. Welch SP, Eads M. Synergistic interactions of endog-
enous opioids and cannabinoid systems. Brain Res 
1999; 848: 183–190. 
115. Massi P, Vaccani A, Romorini S, Parolaro D. Compara-
tive characterization in the rat of the interaction between 
cannabinoids and opiates for their immunosuppressive 
and analgesic effects. J Neuroimmunol 2001; 117: 116–
124.
116. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz 
JJ, Ramos A, Fuentes JA. Pharmacological and bio-
chemical interactions between opioids and cannabi-
noids. Trends Pharmacol Sci 1999; 20: 287–294.
117. Cichewicz DL, Martin Z, Smith FL, Welch, SP. En-
hancement of opioid potency with inactive oral admin-
istration of D9-THC: Dose response analysis and recep-
tor characterization. J Pharmacol Exp Ther 1999; 289: 
859–867.
118. Pugh GJ, Smith P, Dombrowski D, Welch SP. The role 
of endogenous opioids in enhancing the antinociception 
produced by the combination of D9-THC and morphine 
in the spinal cord. J Pharmacol Exp Ther 1996; 279: 
608–616.
119. Cichewicz DL, Haller VL, Welch SP. Changes in opioid 
and cannabinoid receptor protein following short-term 
combination treatment with D9-tetrahydrocannabinol 
and morphine. J Pharmacol Exp Ther 2001; 297: 121–
127.
120. Rowen DW, Embrey JP, Moore CH, Welch SP. Anti-
sense oligodeoxynucleotides to Kappa1 receptor en-
hance D9-THC-induced antinociceptive tolerance. 
Pharmacol Biochem Behav 1998; 59: 399-404.
121. Sala M, Braida D, Leone MP, Calcaterra P, Frattola D, 
Gori E. Chronic morphine affects working memory during 
treatment and withdrawal in rats: possible residual long-
term impairment. Behav Pharmacol 1994; 5: 570-580.
122. Vigano D, Cascio MG, Rubino T, Fezza F, Vaccani A, 
Di Marzo V, et al. Chronic morphine modulates the con-
tents of the endocannabinoid, 2-arachidonoyl glycerol, 
in rat brain. Neuropsychopharmacology 2003: 28: 1160-
1167. 
123. Gonthier MP, Hoareau L, Festy F, Matias I, Valenti M, 
Bes-Houtmann S, et al. Identification of the endocan-
nabinoids and related compounds in human fatty cells. 
Obesity 2007; 15: 837-845.
124. Fride E. The endocannabinoid-CB receptor system: A 
new player in the brain-gut-adipose field. Biomed Rev 
2006; 17: 23-42.
125. Kirkham TC, Tucci SA. Endocannabinoids in appetite 
control and the treatment of obesity. CNS Neurol Disord 
Drug Targets 2006; 5: 272–292. 
126. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, 
Járai Z, et al. Leptin-regulated endocannabinoids are 
involved in maintaining food intake. Nature 2001; 410: 
822–825.
127. Di Marzo V, Sepe N, De Petrocellis L, Berger A, Crozier 
G, Fride E, et al. Trick or treat from food endocannabi-
noids? Nature 1998; 396: 636–637.
128. Kirkham TC, Williams CM, Fezza F, Di Marzo V. En-
docannabinoid levels in rat limbic forebrain and hy-
pothalamus in relation to fasting, feeding and satiation: 
stimulation of eating by 2-arachidonoyl glycerol. Br J 
Pharmacol 2002; 136: 550–557. 129. Yoshida R, Ohku-
ri T, Jyotaki M, Yasuo T, Horio N, Yasumatsu K, et al. 
Endocannabinoids selectively enhance sweet taste. Proc 
Natl Acad Sci USA 2010; 107: 935–939.
130. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu 
G, Fattore L, et al. Functional interaction between opi-
oid and cannabinoid receptors in drug self administra-
tion. J Neurosci 2001; 21: 5344–5350.
131. Hungund BL, Basavarajappa BS, Vadasz C, Kunos G, 
Rodriguez de Fonseca F, Colombo G, et al. Ethanol, 
endocannabinoids, and the cannabinoidergic signaling 
system. Alcohol Clin Exp Res 2002; 26: 565–574.
132. Basavarajappa BS, Hungund BL. Chronic ethanol in-
creases the cannabinoid receptor agonist anandamide 
and its precursor N-arachidonoylphosphatidyl-eth-
anolamine in SK-N-SH cells. J Neurochem 1999; 72: 
522–528.
133. Gonza´lez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di 
Marzo V, Ramos JA. Changes in endocannabinoid con-
tents in the brain of rats chronically exposed to nicotine, 
ethanol or cocaine. Brain Res 2002; 954: 73– 81.
134. Beheshtian A, Salmasi AH, Payabvash S, Kiumehr S, 
Nezami BG, Rahimpour S, et al. Role of endogenous 
cannabinoids in ischemia/reperfusion injury following 
45
Biomed Rev 21, 2010
Endocannabinoids, neurotrophins, psychotropic drugs 
testicular torsion in rats. Int J Urol 2008; 15: 449-454.
135. Pacher P, Haskó G. Endocannabinoids and cannabinoid 
receptors in ischaemia–reperfusion injury and precondi-
tioning. Br J Pharmacol 2008; 153: 252–262.
136. Wang H, Xie H, Dey SK. Endocannabinoid signaling 
directs periimplantation events. AAPS J 2006; 8: E425-
E432.
137. Das SK, Paria BC, Chakraborty I, Dey SK. Cannabinoid 
ligand-receptor signaling in the mouse uterus. Proc Natl 
Acad Sci USA 1995; 92 (10): 4332–4336.
138. Maccarrone M, Valensise H, Bari M, Lazzarin N, 
Romanini C, Finazzi-Agrò A. Relation between de-
creased anandamide hydrolase concentrations in human 
lymphocytes and miscarriage. Lancet 2000; 355: 1326–
1329.
139. Munson AE, Harris LS, Friedman MA, Dewey WL, 
Carchman RA. Antineoplastic activity of cannabinoids. 
J Natl Cancer Inst 1975; 55: 597–602.
140. Jia W, Hegde1 VL, Singh NP, Sisco1 D, Grant S, Nagar-
katti M. et al. Δ9-Tetrahydrocannabinol-induced apop-
tosis in jurkat leukemia T cells is regulated by transloca-
tion of bad to mitochondria. Mol Cancer Res 2006; 4: 
549–562
141. Pushkarev VM, Kovzun OI. Antineoplastic and apop-
totic effects of cannabinoids. N-acylethanolamines: pro-
tectors or killers? Exp Oncol 2008; 30: 6-21.
142. Pang Z, Geddes JW. Mechanisms of cell death induced 
by the mitochondrial toxin 3 nitropropionic acid: acute 
excitotoxic necrosis and delayed apoptosis. J Neurosci 
1997; 17: 3064–3073.
143. Jackson SJ, Diemel LT, Pryce G, Baker D. Cannabi-
noids and neuroprotection in CNS inflammatory dis-
ease. J Neurosci 2005; 25: 1904 –1913.
144. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus 
L, Breuer A, Mechoulam R, et al. An endogenous can-
nabinoid (2-AG) is neuroprotective after brain injury. 
Nature 2001; 413: 527–531.
145. Ramirez BG, Blázquez C, Gómez del Pulgar T, Guzmán 
M, de Ceballos ML. Prevention of Alzheimer’s disease 
pathology by cannabinoids: neuroprotection mediated 
by blockade of microglial activation. J Neurosci 2005; 
25: 1904–1913.
146. Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, 
Fernandez E, et al. WIN55212-2, a cannabinoid recep-
tor agonist, protects against nigrostriatal cell loss in the 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse 
model Parkinson’s disease. Eur J Neurosci 2009; 29: 
2177-2186.
147. Lastres-Becker I, Molina-Holgado F, Ramos JA, 
Mechoulam R, Fernández-Ruiz J. Cannabinoids pro-
vide neuroprotection against 6-hydroxydopamine toxic-
ity in vivo and in vitro: relevance to Parkinson’s disease. 
Neurobiol Dis 2005; 19: 96–107.
148. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotch-
ie JM. Enhanced levels of endogenous cannabinoids in 
the globus pallidus are associated with a reduction in 
movement in an animal model of Parkinson’s disease. 
Faseb J 2000; 14: 1432-1438.
149. Centonze D, Rossi S, Finazzi-Agrò A, Bernardi G, 
Maccarrone M. The Endocannabinoid system in multi-
ple sclerosis and amyotrophic lateral sclerosis. Int Rev 
Neurobiol 2007; 82: 171-186.
150. Huntley A. A review of the evidence for efficacy of 
complementary and alternative medicines in MS. Int 
MS J 2006; 13: 5–12.
151. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, 
Huffman JW, et al. Cannabinoids control spasticity and 
tremor in a multiple sclerosis model. Nature 2000; 404: 
84–87.
152. Arevalo-Martin A, Vela JM, Molina-Holgado E, Bor-
rell J, Guaza C. Therapeutic action of cannabinoids in 
a murine model of multiple sclerosis. J Neurosci 2003; 
23: 2511–2516.
153. Cabranes A, Pryce G, Baker D, Fernández-Ruiz J. 
Changes in CB1 receptors in motor-related brain struc-
tures of chronic relapsing experimental allergic enceph-
alomyelitis mice. Brain Res 2006; 1107 : 199-205.
154. Molina-Holgado E, Vela JM, Arévalo-Martín A, Al-
mazán G, Molina-Holgado F, Borrell J, et al. Cannabi-
noids promote oligodendrocyte progenitor survival: 
involvement of cannabinoid receptors and phosphati-
dylinositol-3 kinase/Akt signaling. J Neurosci 2002; 22: 
9742-9753.
155. Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang 
W, Nithipatikom K, et al. Cultured rat microglial cells 
synthesize the endocannabinoid 2-Arachidonylglyc-
erol, which increases proliferation via a CB2 receptor-
dependent mechanism. Mol Pharmacol 2004; 65: 999-
1007.
156. Fowler CJ. Pharmacological properties and therapeutic 
possibilities for drugs acting upon endocannabinoid re-
ceptors. Curr Drug Targets CNS Neurol Disord 2005; 4: 
685-696.
157. Shen M, Thaye, SA. Cannabinoid receptor agonists pro-
tect cultured rat hippocampal neurons from excitotoxic-
ity. Mol Pharmacol 1998; 54: 459–462.
46
Biomed Rev 21, 2010
Hassanzadeh
158. Hampson AJ, Grimaldi M. Cannabinoid receptor acti-
vation and elevated cyclic AMP reduce glutamate neu-
rotoxicity. Eur J Neurosci 2001; 13: 1529–1536.
159. Nagayama T, Sinor AD, Simon RP, Chen J, Graham 
SH, Jin K, Greenberg DA. Cannabinoids and neuro-
protection in global and focal cerebral ischemia and in 
neuronal cultures. J Neurosci 1999; 19: 2987–2995.
160. Sinor AD, Irvin SM, Greenberg DA. Endocannabinoids 
protect cerebral cortical neurons from in vitro ischemia 
in rats. Neurosci Lett 2000; 278: 157–160.
161. Van der Stelt M, Veldhuis WB, Maccarrone M, Bär PR, 
Nicolay K, Veldink GA, et al. Acute neuronal injury, ex-
citotoxicity and the endocannabinoid system. Mol Neu-
robiol 2002; 26: 317-346.
162. Diana MA, Bregestovski P. Calcium and endocannabi-
noids in the modulation of inhibitory synaptic transmis-
sion. Cell Calcium 2005; 37: 497–505. 
163. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl 
C. Neuroprotective properties of cannabinoids against 
oxidative stress: role of the cannabinoid receptor CB1. J 
Neurochem 2002; 80: 448-456.
164. Croci T, Landi M, Galzin AM, Marini P. Role of can-
nabinoid CB1 receptors and tumor necrosis factor-α 
in the gut and systemic anti-inflammatory activity of 
SR141716 (Rimonabant) in rodents. Br J Pharmacol 
2003; 140(1): 115–122.
165. Van der Stelt M, Di Marzo V. Cannabinoid receptors 
and their role in neuroprotection. Neuromolecular Med 
2005; 7: 37-50. 
166. Marsicano G, Goodenough S, Monory K, Hermann H, 
Eder M, Cannich, A. CB1 cannabinoid receptors and on-
demand defense against excitotoxicity. Science 2003: 
302: 84-88.
167. Khaspekov LG, Brenz Verca MS, Frumkina LE, Her-
mann H, Marsicano G, Lutz B. Involvement of brain-
derived neurotrophic factor in cannabinoid receptor-
dependent protection against excitotoxicity. Eur J Neu-
rosci 2004; 19: 1691-1698.
168. Barna I, Zelena D, Arszovszki AC, Ledent C. The role of 
endogenous cannabinoids in the hypothalamo-pituitary-
adrenal axis regulation: in vivo and in vitro studies in CB1 
receptor knockout mice. Life Sci 2004; 75: 2959-2970.
169. Hassanzadeh P, Hassanzadeh A. The role of the endo-
cannabinoids in suppression of the HPA axis activity by 
doxepin. Iran J Basic Med Sci 2011 (in press).
170. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Cam-
polongo P, Solinas M, et al. Antidepressant-like activity 
and modulation of brain monoaminergic transmission 
by blockade of anandamide hydrolysis. Proc Natl Acad 
Sci USA 2005; 102: 18620–18625.
171. Manji HK, Drevets WC, Charney DS. The cellular neu-
robiology of depression. Nat Med 2001; 7: 541–547.
172. Hill MN, Gorzalka BB. Is there a role for the endocan-
nabinoid system in the etiology and treatment of melan-
cholic depression? Behav Pharmacol 2005; 16: 333–352. 
173. Hill MN, Hillard CJ, Bambico FR, Patel S, Gorzalka 
BB, Gobbi G. The therapeutic potential of the endocan-
nabinoid system for the development of a novel class of 
antidepressants. Trends Pharmacol Sci 2009; 30 : 484-
493. 174. Haller J, Varga B, Ledent C, Barna I, Freund 
TF. Context dependent effects of CB1 cannabinoid gene 
disruption on anxiety-like and social behaviour in mice. 
Eur J Neurosci 2004; 19: 1906–1912. 
175. Robson P. Therapeutic aspects of cannabis and cannabi-
noids. Br J Psychiatry 2001; 178: 107–115. 
176. Navarro M, Hernandez E, Munoz RM, del Acro I, Vil-
lanua MA, Carrera MRA. Acute administration of the 
CB1 cannabinoid receptor antagonist SR141716A in-
duces anxiety-like responses in the rat. Neuroreport 
1997; 8: 491-496.
177. Patel S, Hillard CJ. Pharmacological evaluation of can-
nabinoid receptor ligands in a mouse model of anxiety: 
further evidence for an anxiolytic role for endogenous 
cannabinoid signaling. J Pharmacol Exp Ther 2006; 
318: 304-310.
178. Jenny M, Schröcksnadel S, Überall F, Fuchs D. The po-
tential role of cannabinoids in modulating serotonergic 
signaling by their influence on tryptophan metabolism. 
Pharmaceuticals 2010; 3: 2647-2660. 
179. Galve-Roperh I, Aguado T, alazuelos J, Guzmán M. The 
endocannabinoid system and neurogenesis in health and 
disease. Neuroscientist 2007; 13: 109-114.
